Biomarkers in GIST: partly ready for prime-time use.
Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.
Blanke
Charles D
CD
University of British Columbia and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada. cblanke@bccancer.bc.ca
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D018450:Disease Progression; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D000077210:Sunitinib; D013997:Time Factors
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib